Doxycycline and therapeutic targeting of the DNA damage response in cancer cells : old drug, new purpose by Peiris-Pagès, M et al.
Oncoscience696www.impactjournals.com/oncoscience
www.impactjournals.com/oncoscience Oncoscience 2015, Vol.2, No.8
Doxycycline and therapeutic targeting of the DNA damage 
response in cancer cells: old drug, new purpose
Maria Peiris-Pagès1,2, Federica Sotgia1,2, Michael P. Lisanti1,2
1 The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK
2 The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, 
UK
Correspondence to: Michael P. Lisanti, email: michaelp.lisanti@gmail.com
Keywords: doxycycline, drug repurposing, DNA-PK, DNA damage response, antibiotics for cancer therapy, cancer stem cells, 
mitochondria, cancer metabolism
Received: August 11, 2015 Accepted: August 17, 2015 Published: August 24, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
There is a small proportion of cells within a tumour with self-renewing properties, 
which is resistant to conventional therapy, and is responsible for tumour initiation, 
maintenance and metastasis. These cells are known as cancer stem cells (CSCs) or 
tumour-initiating cells (TICs) [1]. Recent publications identify several antibiotics, 
such as salinomycin or doxycycline, as selective CSCs inhibitors [2-4]. However, the 
mechanisms of action of these antibiotics on CSCs are not fully understood.
Doxycycline effects on DNA repair
Previous studies performed in our lab showed 
higher levels of mitochondrial proteins in breast CSCs, 
defined by their capability to grow in suspension as 
mammospheres, compared with the bulk of cancer cells 
grown under regular conditions [2]. That discovery led 
to the hypothesis that such increase in mitochondrial 
protein abundance could be reversed by treating these 
mammospheres with antibiotics, hence eradicating the 
CSCs population, as several classes of FDA-approved 
antibiotics can inhibit mitochondrial protein synthesis. 
Indeed several antibiotics, such as doxycycline, were 
able to inhibit mammosphere formation [2]. However, the 
mechanism of action of doxycycline remained unidentified 
and in a further effort to elucidate it, our lab recently 
published a report demonstrating reduced expression of 
proteins associated with mitochondrial metabolism, EMT, 
protein synthesis, and more curiously, with DNA damage 
response after doxycycline treatment in a breast cancer 
cell line [5]. Particularly, one of the best doxycycline 
targets identified by our quantitative proteomics analysis 
was DNA-PK, the catalytic subunit of the DNA-dependent 
protein kinase, which is required for proper NHEJ (non-
homologous end-joining) DNA repair [6], for maintenance 
of mitochondrial DNA integrity and copy number [7], 
and it confers resistance to radiation and chemotherapy 
in cancer cells [8]. Interestingly, DNA-PK was also 
found to be up-regulated in mammospheres, and its 
genetic knock-down or pharmacological inhibition using 
either doxycycline or an established DNA-PK inhibitor 
(NU7441) blocked that mammosphere formation. In 
fact, a closer look at the chemical structure reveals that 
doxycycline is a reduced carba-analogue of other DNA-
PK inhibitors (Figures 1 and 2), although the direct 
interaction between doxycycline and DNA-PK still needs 
to be proved. Mechanistically, doxycycline treatment 
reduced not only the general metabolic state of breast 
cancer cells and their capacity to resist anoikis, but also 
inhibited their antioxidant response and several stem-
related signalling pathways including Wnt, Shh, Notch, 
TGFβ and STAT3, the inhibition of which induces anoikis 
and radio and chemosensitivity [1, 9-14]. DNA-PK has 
even been shown to directly interact with LEF1, which 
acts downstream in the Wnt signaling [15]. Similarly, 
salinomycin, another antibiotic, has also been reported to 
act on breast CSC by inhibiting Wnt pathway [3].
Radiation and chemotherapy induce DNA damage, 
which is lethal to the cells if it is not repaired. It is now 
known that CSCs protect themselves from DNA damaging 
treatment by regulating cell cycle, by scavenging more 
efficiently the reactive oxygen species and by enhancing 
their DNA repair capability. Several studies demonstrate 
that CSCs have an activated DNA repair process, as well 
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as a more robust activation of DNA damage response 
genes and proteins than non-stem cells [16], which 
makes them resistant to cancer therapy. In line with these 
results, our study also shows the effects of doxycycline on 
increasing sensitivity to radiation treatment. 
Doxycycline effects on neddylation and 
ubiquitination
Recent clinical trials involving doxycycline have 
already shown positive therapeutic effects in lymphoma 
patients [17]. In agreement with that, a recent publication 
by Pulvino et al., demonstrated that doxycycline 
inhibits diffuse large B cell lymphoma growth in vitro 
and in vivo, in part via inhibition of CSN5 activity and 
reduction of HSP90 levels and function [18]. CSN5 
is a member of the COP-9 signalosome complex that 
inhibits neddylation, a process similar to ubiquitination. 
Genetic or pharmacological inhibition of CSN5 using 
doxycycline was able to decrease CSN5 deneddylation 
function, impairing cell survival in diffuse large B cell 
lymphoma cells. Altogether these results indicated that 
doxycycline treatment induces proteasomal degradation 
by increasing ubiquitination and neddylation in lymphoma 
cells. In addition, the study demonstrated that doxycycline 
treatment causes cell cycle arrest and inhibits NFkB and 
STAT3 signalling, as our experiments show. 
Finally, in the report the authors mention that they 
observed synergetic cytotoxic effects of doxycycline 
and several chemotherapeutic agents in diffuse large 
B cell lymphoma, giving another indication that 
doxycycline targets chemoresistant CSCs. In contrast 
with that, though, it has been shown in human cells that 
inhibition of neddylation sensitizes cells to radiotherapy 
and chemotherapeutic agents although the mechanisms 
behind this synergy are not fully understood and have 
not been consistent [19]. Nevertheless, it is now well 
established that an enhanced DNA damage response is one 
of the features that allow CSCs to overcome treatment. 
The efficiency of DNA damage detection and repair 
requires the recruitment and modification of a complex 
protein network. The DNA damage response is a tightly 
regulated process involving reversible post-translational 
modifications such as ubiquitination and neddylation, 
which regulate protein stability and function, preventing 
de novo protein synthesis [16, 19]. 
To sum up, in addition to the well-known 
doxycycline anti-microbial and anti-inflammatory effects, 
and its ability to inhibit metal membrane proteinases 
(MMPs) by chelating the essential zinc ions of these 
enzymes [20], this new evidence in breast cancer and 
lymphoma cells indicate that doxycycline has also a 
clear impact in regulating the DNA damage response, 
including DNA repair (DNA-PK), ubiquitination and 
neddylation (CSN5 and HSP90), as well as in supressing 
Figure 1: Chemical structures of three known DNA-PK inhibitors A) NU-7026, B) NU-7441, C) KU-0060648 and D) a 
chemical entity common to all of these DNA-PK inhibitors.
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different developmental and EMT pathways (Wnt, Notch, 
Hedgehog, TGFβ and STAT3), all processes found to be 
reinforced in CSCs and to confer resistance to anoikis 
and conventional therapies [1, 9, 11-14]. A successful 
cancer therapy should aim to eliminate all cancer cells, 
including the intrinsically resistant CSC population, which 
ultimately will give rise to recurrence and metastasis. That 
is why the concept that doxycycline and other antibiotics 
may reduce the viability and growth of the CSC population 
is of great importance and should be further investigated. 
Last but not least, doxycycline is an excellent 
example of how existing, inexpensive, well-tolerated drugs 
might be repurposed not only as new cancer therapeutic 
agents, but also might provide the new insights needed 
to fully understand CSC traits in tumours. Likewise it is 
important to properly establish the bioequivalent dose 
required to block CSCs. 
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